Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
9 evidence topics · 11 sources
Summary
10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and Tice et al. (2022) state that about 20,000 patients with generalized myasthenia gravis are estimated to be intolerant or to have an inadequate response to conventional treatment options. Upward of thirty percent of patients do not benefit from complement inhibition. In claims data from 8833 patients with generalized myasthenia gravis, incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use, compared with 52.3% without, and annual all-cause costs were more than twice as high ($76,381 vs $35,309). Soliris increases the risk of serious meningococcal infections, requires meningococcal vaccination at least 2 weeks before the first dose, and, like Zilbrysq, is available only through a REMS program. Vyvgart may increase the risk of infection. Gilhus et al. list the need for meningococcal vaccination before starting treatment, recommended pneumococcal vaccination, and regular intravenous or subcutaneous injections as limitations, and a company presentation states that 40% of patients discontinue Vyvgart within one year. ICER estimated an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG for eculizumab, and high drug costs limit access to complement inhibitors and FcRn blockers in most countries.
Refractory disease despite conventional immunosuppression
“Definition of refractory MG. PIS3 is unchanged or worse after corticosteroids and at least 2 other IS agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by patient and physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incomplete response to targeted biologics
“There remain upward of thirty percent of patients who do not benefit from complement inhibition, which demonstrates the importance of other mechanisms of autoantibody action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is a pressing need for such advancements, especially considering the proliferation of multiple costly treatment options with substantial minorities of patients showing a poor response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid toxicity and associated costs
“Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GC acute and chronic toxicities and costs tended to increase with increasing GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors
“One case of meningococcal meningitis occurred, despite vaccination in the OLE and the patient was successfully treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vaccination against Neisseria meningitidis (both meningococcal conjugate Men ACWY and serogroup B or MenB) is required at least 2 weeks before starting treatment with eculizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration burden: infusion schedules and repeated injections
Treatment persistence with FcRn blockade: company-cited claims data
Cost and cost-effectiveness of targeted biologics
“For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.11 At this estimated price, efgartigimod has an the incremental cost per QALY/evLYG of $2,076,000 (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Very high drug costs have limited the accessibility to treatment in most countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In common with complement inhibitors, the availability of FcRn blockers is limited by high drug costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote